Thomas Burnell - Interpace Biosciences CEO Pres
| IDXGDelisted Stock | USD 2.20 0.00 0.00% |
Insider
Thomas Burnell is CEO Pres of Interpace Biosciences
| Age | 61 |
| Phone | 855 776-6419 |
| Web | www.interpacediagnostics.com |
Interpace Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2602) % which means that it has lost $0.2602 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8481) %, meaning that it created substantial loss on money invested by shareholders. Interpace Biosciences' management efficiency ratios could be used to measure how well Interpace Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Sanjiv Suri | Trinity Biotech plc | 65 | |
| Atul Butte | Personalis | N/A | |
| Tracy Curley | iSpecimen | 62 | |
| Tony Kalajian | OncoCyte Corp | N/A | |
| Michael MD | Sera Prognostics | N/A | |
| Steven Graves | Sera Prognostics | N/A | |
| Cavan Redmond | OncoCyte Corp | 58 | |
| Yusheng Han | Burning Rock Biotech | 46 | |
| Ekkehard MD | OncoCyte Corp | N/A | |
| MD FACR | Exagen Inc | N/A | |
| Douglas Ross | OncoCyte Corp | N/A | |
| Xavier MS | bioAffinity Technologies, | 55 | |
| Alex Arzeno | Intelligent Bio Solutions | N/A | |
| Jill Mullan | iSpecimen | 59 | |
| MBA MBA | Sera Prognostics | 70 | |
| John West | Personalis | 67 | |
| John Boniface | Sera Prognostics | 63 | |
| Maria JD | bioAffinity Technologies, | 69 | |
| Robert Seitz | OncoCyte Corp | 60 | |
| Ryan Douglas | Exagen Inc | N/A | |
| Maria JD | bioAffinity Technologies Warran | 69 | |
Management Performance
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 |
Interpace Biosciences Leadership Team
Elected by the shareholders, the Interpace Biosciences' board of directors comprises two types of representatives: Interpace Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Interpace. The board's role is to monitor Interpace Biosciences' management team and ensure that shareholders' interests are well served. Interpace Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Interpace Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Burnell, CEO Pres | ||
| Sydney Finkelstein, Chief Officer | ||
| Patrick Kane, VP Controller | ||
| Jody Campbell, Chief Officer | ||
| Thomas Freeburg, Chief Accounting Officer and Principal Accounting Officer | ||
| Susanne Reilly, Chief Officer |
Interpace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Interpace Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 4.27 M | ||||
| Shares Owned By Insiders | 28.12 % | ||||
| Number Of Shares Shorted | 47.35 K | ||||
| Price To Earning | (1.07) X | ||||
| Price To Book | 10.04 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |